Clinical Trial Update: Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus [Phase 2]

View source ↗

Summary

A Phase 2 study of ARC-520 in HBeAg-positive chronic hepatitis B was terminated, with results posted in November 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ARC-520

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Chronic Hepatitis B | Phase 2 | Status: TERMINATED | Results posted: 2017-11-01